Precision Medicine in Pediatric Oncology

Release Date: February 06, 2020
Expiration Date: February 06, 2021
Media: Internet - based

Activity Overview

This continuing medical education (CME) activity is designed to inform healthcare providers who care for pediatric oncology patients of the key principles and components of precision medicine in pediatric oncology. The in-depth program will cover the current approaches to molecular testing in the pediatric population and the genetic abnormalities that are known to be important in the setting of pediatric oncology. In addition, safety and efficacy data of ongoing trials using tropomyosin receptor kinase (TRK) inhibitors in pediatric oncology is discussed.

Benefits of Participating

• Learn the key principles and components of precision medicine in pediatric oncology
• Outline the genetic abnormalities that are known to be important in the setting of pediatric oncology and the current approaches to molecular testing in the pediatric population
• Implement recent clinical trial findings regarding the efficacy and safety of TRK inhibitors in the treatment of pediatric patients with NTRK fusions

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Describe the key principles and components of precision medicine in pediatric hematology-oncology
• Discuss the current approaches to molecular testing in the pediatric population and the genetic abnormalities that are known to be important in the setting of pediatric oncology
• Consider safety and efficacy data of ongoing trials using tropomyosin receptor kinase (TRK) inhibitors in pediatric oncology

Faculty, Staff, and Planners’ Disclosures

Faculty

Theodore Laetsch, MD
Associate Professor, Department of Pediatrics
Norma and Jim Smith Professor of Clinical Excellence
Eugene P. Frenkel, M.D. Scholar in Clincial Medicine
Harold C Simmons Comprehensive Cancer Center
Univeristy University of Texas Southwestern Medical Center
Experimental Therapeutics Program Leader
Children’s Health
Dallas, TX

Disclosures: Grant/Research Support: Bayer, Turning Point Therapeutics, Inc., Novartis, Pfizer; Consultant: Bayer, Novartis.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CE activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER^®.

This activity is funded by PER^®.